“Changes in soluble CD163 indicate monocyte involvement in cognitive deficits in Parkinson’s disease”
Authors:
Preprint
Abstract
Parkinson’s disease is a neurodegenerative disorder with a significant immune component. Numerous studies have reported alterations on immune biomarkers in CSF and serum that associate with symptoms in PD patients. However, it is unclear, which specific immune cells are responsible for the changes in those biomarkers; since most of these cytokines or chemokines, can be produced by a variety of immune cells, or even neurons or glia cells in the brain. Here, we investigate a monocyte/macrophage-specific biomarker: sCD163, the soluble form of the receptor CD163. Our data from tow cohorts show that the CSF-sCD163 increases as the disease progresses, together with a correlated increase in PD-specific as well as neurodegeneration-associated disease biomarkers: alpha-synuclein, tau, and phosphorylated-Tau. Moreover, CSF-sCD163 levels were inversely correlated to the cognitive scores MMSE and MOCA, with higher sCD163 indicating lower cognitive capacity. sCD163 was also increased in serum, although only in female PD patients, suggesting a gender distinctive monocyte-related immune response. CSF-sCD163 also correlated with molecules associated with endothelial cells, tissue infiltration, and activation of B cells and T cells in the PD patients. This suggests activation of both the adaptive and the innate immune system along with recruitment of lymphocytes and monocytes to sites of inflammation in the brain. In serum, sCD163 was associated with pro-inflammatory cytokines and acute phase proteins, suggesting a relation to chronic systemic inflammation. Interestingly, our in vitro study suggests that sCD 163 might enhance alpha-synuclein uptake by myeloid cells without direct binding, thus participating in the clearance of alpha-synuclein. Accordingly, our data supports sCD163 as a potential cognition-related biomarker in PD and corroborates a role for monocytes both in peripheral and brain immune responses that could have direct consequences in the handling of alpha-synuclein.Keywords
All Related Versions
- Published version: Movement Disorders, 36 (4), 963.
This publication has 85 references indexed in Scilit:
- The intrathecal CD163‐haptoglobin–hemoglobin scavenging system in subarachnoid hemorrhageJournal of Neurochemistry, 2012
- ADAM17: a molecular switch to control inflammation and tissue regenerationTrends in Immunology, 2011
- Serum urate and probability of dopaminergic deficit in early “Parkinson's disease”Movement Disorders, 2011
- Differential Roles for Endothelial ICAM-1, ICAM-2, and VCAM-1 in Shear-Resistant T Cell Arrest, Polarization, and Directed Crawling on Blood–Brain Barrier EndotheliumThe Journal of Immunology, 2010
- Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson diseaseNeurology, 2009
- Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson diseaseJournal of Clinical Investigation, 2008
- Alpha‐synuclein and its disease‐causing mutants induce ICAM‐1 and IL‐6 in human astrocytes and astrocytoma cellsThe FASEB Journal, 2006
- Tumor Necrosis Factor-α-converting Enzyme (TACE/ADAM-17) Mediates the Ectodomain Cleavage of Intercellular Adhesion Molecule-1 (ICAM-1)Journal of Biological Chemistry, 2006
- Interaction of soluble CD163 with activated T lymphocytes involves its association with non‐muscle myosin heavy chain type AImmunology & Cell Biology, 2004
- Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations The Movement Disorder Society Task Force on rating scales for Parkinson's diseaseMovement Disorders, 2004